Supporting Pediatric RSV Clinical Trials Through Close Epidemiological Surveillance During the SARS ‐ CoV ‐2 Pandemic
Pharmacology Research & Perspectives · 2025
DOI: 10.1002/prp2.70112 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacology Research & Perspectives, 2025. Verfasst von Rennie Joshi und 4 weiteren Autor:innen. Beteiligte Einrichtung: Merck Sharp & Dohme LLC, Rahway, New Jersey, USA. Hauptthemen laut MEDLINE: Respiratory Syncytial Virus Infections, COVID-19, Clinical Trials as Topic, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Merck.
Abstract (Originalsprache)
Clesrovimab, an extended half‐life monoclonal antibody, aims to protect infants for an entire RSV season. The pandemic impacted RSV epidemiology and strategies were implemented to support clesrovimab trials. Near real‐time monitoring of data showed minimal RSV activity in 2020. In 2021, RSV resurged early in some countries and was delayed in others, resulting in a change in trial enrollment strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Merck Sharp & Dohme LLC, Rahway, New Jersey, USA.
ORCID-Profile: Rennie Joshi
Förderung
- Merck
Zitieren
APA
Joshi, R., Nahhas, G. J., Arriola, C. S., Saddier, P., & Guerra, A. (2025). Supporting Pediatric RSV Clinical Trials Through Close Epidemiological Surveillance During the SARS ‐ CoV ‐2 Pandemic. Pharmacology Research & Perspectives. https://doi.org/10.1002/prp2.70112
Vancouver
Joshi R, Nahhas GJ, Arriola CS, Saddier P, Guerra A. Supporting Pediatric RSV Clinical Trials Through Close Epidemiological Surveillance During the SARS ‐ CoV ‐2 Pandemic. Pharmacology Research & Perspectives. 2025. doi:10.1002/prp2.70112
BibTeX
@article{Joshi2025,
author = {Joshi, Rennie and Nahhas, Georges J and Arriola, Carmen S and Saddier, Patricia and Guerra, Andrea},
title = {Supporting Pediatric RSV Clinical Trials Through Close Epidemiological Surveillance During the SARS ‐ CoV ‐2 Pandemic},
journal = {Pharmacology Research & Perspectives},
year = {2025},
doi = {10.1002/prp2.70112}
}
EUVIMED